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Abstract
Background: Adipose tissue-derived mesenchymal stromal cells (AT-MSCs) are frequently used to treat equine
tendinopathies. Up to now, knowledge about the fate of autologous AT-MSCs after intralesional injection into
equine superficial digital flexor tendons (SDFTs) is very limited. The purpose of this study was to monitor the
presence of intralesionally injected autologous AT-MSCs labelled with superparamagnetic iron oxide (SPIO)
nanoparticles and green fluorescent protein (GFP) over a staggered period of 3 to 9 weeks with standing
magnetic resonance imaging (MRI) and histology.
Methods: Four adult warmblood horses received a unilateral injection of 10 × 106 autologous AT-MSCs into surgically
created front-limb SDFT lesions. Administered AT-MSCs expressed lentivirally transduced reporter genes for GFP and
were co-labelled with SPIO particles in three horses. The presence of AT-MSCs in SDFTs was evaluated by
repeated examinations with standing low-field MRI in two horses and post-mortem in all horses with Prussian
blue staining, fluorescence microscopy and with immunofluorescence and immunohistochemistry using anti-GFP
antibodies at 3, 5, 7 and 9 weeks after treatment.
Results: AT-MSCs labelled with SPIO particles were detectable in treated SDFTs during each MRI in T2*- and
T1-weighted sequences until the end of the observation period. Post-mortem examinations revealed that all
treated tendons contained high numbers of SPIO- and GFP-labelled cells.
(Continued on next page)
* Correspondence: Florian.Geburek@tiho-hannover.de
1Clinic for Horses, University of Veterinary Medicine Hannover, Foundation,
Bünteweg 9, 30559 Hannover, Germany
Full list of author information is available at the end of the article
© 2016 Geburek et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Geburek et al. Stem Cell Research & Therapy  (2016) 7:21 
DOI 10.1186/s13287-016-0281-8
(Continued from previous page)
Conclusions: Standing low-field MRI has the potential to track SPIO-labelled AT-MSCs successfully. Histology,
fluorescence microscopy, immunofluorescence and immunohistochemistry are efficient tools to detect labelled AT-
MSCs after intralesional injection into surgically created equine SDFT lesions. Intralesional injection of 10 × 106 AT-MSCs
leads to the presence of high numbers of AT-MSCs in and around surgically created tendon lesions for up to 9 weeks.
Integration of injected AT-MSCs into healing tendon tissue is an essential pathway after intralesional administration.
Injection techniques have to be chosen deliberately to avoid reflux of the cell substrate injected. In vivo low-field MRI may
be used as a non-invasive tool to monitor homing and engraftment of AT-MSCs in horses with tendinopathy of the SDFT.
Keywords: Horse, Superficial digital flexor tendon, Superparamagnetic iron oxide particles, SPIO, Prussian blue staining,
Green fluorescent protein
Background
Injury of the superficial digital flexor tendon (SDFT) is
common, especially in thoroughbred racehorses [1].
Therapy with adipose-derived nucleated cells and adipose
tissue-derived mesenchymal stromal cells (AT-MSCs) has
shown promising results when treating both experimental
tendonitis [2–5] and naturally occurring tendon and liga-
ment injuries in horses [6, 7]. To further investigate the
potential regenerative, immunomodulatory and inflamma-
tory modulating effect of MSC therapy, knowledge of the
distribution, kinetics and engraftment of the injected cells
in the target tissue is of utmost interest [8]. Bone marrow-
derived MSCs (BM-MSCs) and embryonic-like stem cells
(ESCs) have been traced after labelling with green fluores-
cent protein (GFP) and were detectable in the treated
tendon for up to 90 days [9, 10]. Whereas estimated BM-
MSC survival was less than 5 % after 10 days, ESC num-
bers were at a constant level for 90 days [10]. Compared
with MSCs from other sources, AT-MSCs show expres-
sion of extracellular matrix proteins with the highest colla-
gen 1A2-to-collagen 3A1 ratios. Moreover, AT-MSCs
display the second highest expression of the tendon
markers tenascin-C and scleraxis [11], suggesting that AT-
MSCs may be of special benefit in the treatment of equine
tendinopathy. However, knowledge about the fate of au-
tologous AT-MSCs after intralesional injection into equine
SDFTs is marginal. As recently revealed, AT-MSCs
labelled with nanocrystals were detectable in peripheral
blood for 72 h and 7 days after implantation as well as in
SDFT tissue 7 days after intralesional injection in an
equine collagenase tendonitis model [12].
Labelling with superparamagnetic iron oxide (SPIO)
nanoparticles is a technique to track MSCs assisted by
magnetic resonance imaging (MRI) because of the
strength of the signal change per unit of metal provided,
particularly in T2*-weighted images [13]. By means of
this technique, cells can be monitored non-invasively
in vivo and at post-mortem histology by Prussian blue
staining [14]. In contrast, GFP-based labelling tech-
niques are dependent on tissue biopsies or even larger
specimen, thus making euthanasia of the treated animal
necessary [10]. In vitro studies have shown that con-
trolled labelling of MSCs with SPIO nanoparticles
neither caused death of rabbit BM-MSCs nor inhibited
their proliferation [15]. A recent equine study has pro-
vided evidence that viability did not differ between
SPIO-labelled and unlabelled BM-MSCs and umbilical
cord blood MSCs. However, doubling time increased in
SPIO-labelled MSCs compared with unlabelled cells
[16]. In a rodent study, SPIO nanoparticles could be
tracked in vivo for up to 4 weeks after subcutaneous im-
plantation [17]. At the same time, in a different rodent
study investigating the presence of SPIO-labelled BM-
MSCs at a tendon-to-bone interface for up to 7 days, a
reliable tracing of labelled cells was impossible and this
was due to the similar signal intensity of cells and ten-
don tissue on T2-weighted MRI images [18]. As recently
pointed out in an equine cadaver study, SPIO-labelled
BM-MSCs are detectable immediately after intralesional
SDFT injection by using 1.5-Tesla MRI [16].
The present pilot study aimed at testing whether
standing low-field MRI has the potential to monitor
the fate of intralesionally injected AT-MSCs labelled
with SPIO particles in vivo and at monitoring the
presence of AT-MSCs that were co-labelled with GFP
histologically for up to 9 weeks in a surgical model of
equine tendinopathy.
Methods
Four warmblood horses (two stallions, one mare and
one gelding) between 1 and 4 years old were objects
of this study. Pre-existing tendon injury was excluded
by clinical examination, B-mode ultrasonography and
ultrasonographic tissue characterization (UTC) (UTC
2009; UTC Imaging, Stein, The Netherlands). The
study was approved by the animal welfare officer of the
University of Veterinary Medicine Hannover, Foundation,
Germany, and the ethics committee of the responsible
German federal state authority in accordance with the
German Animal Welfare Law (Lower Saxony State
Office for Consumer Protection and Food Safety, Az.
33.9-42502-04-08/1622).
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Collection of subcutaneous fat, AT-MSC isolation, and culture
After sedation of the horses, approximately 1–2 g of
subcutaneous fat was harvested from the left coccygeal
region at the base of the tail 8 or 9 days prior to surgical
creation of standardized SDFT lesions. AT-MSCs were
isolated and cultured as described elsewhere [4]. They
were defined by the presence of markers CD44, CD90,
CD105 and CD117 and the absence of CD34 and CD45.
Labelling with lentiviral plasmid and superparamagnetic
iron oxide particles
After the addition of 10 μg/ml polybrene, the cultured
AT-MSCs of all horses were incubated with lentivirus
particles with a copGFP (hUbiC Promoter) for 48 h. The
efficacy of transfection was controlled by fluorescence
microscopy during passage 1 (Fig. 1) and by flow cyto-
metric analysis (Fig. 2) which was performed on a BD
FACSCanto™ II with BD FACSDiva™ 8.0.1 software (BD
Biosciences, Franklin Lakes, NJ, USA). For excitation,
the 488-nm laser line was used. Debris, dead or damaged
cells as well as cell aggregates were excluded from fur-
ther analysis according to forward scatter (FSC) and side
scatter (SSC) properties (gate P1 and P2). For the detection
of GFP fluorescence intensity, a combination of a 502
low-pass (LP) and 530/30 band-pass (BP) filter in
front of the photomultiplier tube (PMT) detector
(488-E) was employed. Detection sensitivity was set with a
non-expressing control sample. The GFP-positive gate
(P3) was set on the basis of the negative control popula-
tion to include 0.0 % positive events. The mean efficacy of
transfection was estimated to be 99 % after passage 0
(horse 2) and 63 %, 62 %, and 64 % after passage 2 (horses
1, 3 and 4) as determined by three analyses, respectively.
Additionally, AT-MSCs from horses 1, 2 and 4 were
labelled by incubation with 45- to 60-nm SPIO particles
coated with carboxydextran (Resovist™, SHU 555A;
Schering AG, Berlin, Germany) in culture medium for
48 h at an SPIO concentration of 60 μg/ml Fe. Following
the incubation, AT-MSCs were rinsed thrice with
phosphate-buffered saline (PBS) solution. After harvest
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Fig. 1 Photomicrographs of cultured adipose-derived mesenchymal stromal cells from horses 1 to 4 after transfection with lentiviral green fluorescent
protein (GFP) construct. Bright field (left), fluorescence (middle) and merged (right) images are shown. Approximately 70–90 % of the cells were positive
for GFP in their cytoplasm during passage 1. Magnification: 10×. Scale bar: 100 μm
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Fig. 2 Flow cytometric analysis of cultured AT-MSCs from horses 1 to 4 after transfection with lentiviral green fluorescent protein (GFP) construct.
From left to right are (a) scatter plots and (b) histograms, including percentages showing the distribution of GFP-expressing cells in a
non-expressing control sample (ctrl-no GFP) and in samples from horse 2 (I-VP1; passage 0) and horses 1, 3 and 4 (I-VP3, I-VP4 and I-VP2; passage
2) after a single analysis. Green indicates GFP-labelled AT-MSCs, and blue indicates non-labelled AT-MSCs. AT-MSC adipose tissue-derived
mesenchymal stromal cell, FSC-A forward scatter A, GFP green fluorescent protein, SSC-A side scatter A
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of AT-MSCs from passage 0, the total number of cells
was counted and the cell viability evaluated, followed by
sample preparation of 10 × 106 AT-MSCs on ice for
transplantation. Cells not needed for transplantation
were cryopreserved for further experiments.
Creation of superficial digital flexor tendon lesions
Lesions were created in the SDFTs of both front
limbs under general anaesthesia by using a technique
previously described [19–21]. A short longitudinal in-
cision was made axially at the palmar aspect of the
metacarpus just proximal to the digital sheath. A con-
ical obturator (Ø 3.5 mm) from an arthroscope was
introduced through a stab incision into the center of
the SDFT and advanced proximally for 7–8 cm while
carefully avoiding penetration of the epitenon. The
obturator was replaced by an arthroscopic burr (Small
Joint Round Burr ø 3.5 mm, 28204 FB; Karl Storz
GmbH & Co. KG, Tuttlingen, Germany), which was
activated and slowly withdrawn within approximately
20 s. The incisions were closed in a simple interrupted
pattern. The horses received meloxicam (0.6 mg/kg body
weight (bwt) [orally]) the day of surgery and for two con-
secutive days.
Injection of labelled AT-MSCs
The tendon lesions were treated unilaterally with
AT-MSCs at 1 week (horses 2 and 3) and at 3 weeks
(horses 1 and 4) after surgery. Three horses (1, 2
and 4) received AT-MSCs labelled with SPIO parti-
cles. The horses were sedated by using detomidine
hydrochlorid (0.02 mg/kg bwt [IV]) and butorphanol
(0.04 mg/kg bwt [IV]). Additionally the medial and lateral
palmar nerves were anaesthetized with 2 ml of 2 % mepi-
vacaine hydrochlorid 2 cm distal to the carpometacarpal
joint. Approximately 10 × 106 AT-MSCs suspended in
2 ml 0.9 % saline (total volume 3 ml) and divided into ali-
quots of 1.5 ml were injected into the SDFT lesions from
lateral under ultrasonographic guidance by using a 23-G,
1-inch needle. Entrance of the needle was 3 and 5 cm
proximal to the surgical scar. Following the implantation
of the cells, the limbs were dressed with half-limb ban-
dages for 16 days. The contralateral SDFT was treated
with 3 ml of saline in the same manner.
Standing low-field magnetic resonance imaging
In two of the horses treated with SPIO-labelled AT-
MSCs (2 and 4), sequential standing low-field MRI of
the metacarpal regions was performed by using a clinical
0.27-Tesla open magnet (Hallmarq Veterinary Imaging,
Guildford, Surrey, UK) and a fetlock radiofrequency coil.
Front-limb SDFTs were scanned 6 and 33 days after the
intralesional treatment in horse 2 and after 2, 18, 47 and
62 days in horse 4.
Initially the horses were sedated with romifidine
(0.06 mg/kg bwt [IV] and butorphanol (0.01 mg/kg bwt
[IV]). The sedation was prolonged to effect with detomi-
dine (0.01 mg/kg bwt [IV]). After positioning of the
metacarpal regions in the isocenter of the magnet, the
following MRI sequences and variables were applied:
transverse gradient-echo T1-weighted, TR (relaxation
time): 50 ms, TE (echo time): 8.0 ms, FA (flip angle): 50°,
matrix size: 170 × 130, number of excitations: 1; trans-
verse gradient-echo T2*-weighted, FA: 25°, matrix size:
170 × 126; number of excitations: 1; transverse STIR, TR:
2260 ms, TE: 22.0 ms, FA: 90°, matrix size: 168 × 168,
number of excitations: 8. The field-of-view angle was
170 × 170 mm, the slide width was 5.0 mm and the gap
width was 6.0 mm.
Follow-up
Following the creation of the lesions, the horses received
box rest for 3 weeks. Thereafter they were exercised in
accordance with a protocol adapted from Bosch et al.
(2010) [21] until euthanasia: From week 4 to 6, they
were walked for 10 min once a day on a treadmill.
During week 7 to 9, walking was extended to 20 min
once daily. After sedation with xylazine (0.4 mg/kg bwt
[IV]) and levomethadone (0.05 mg/kg bwt [IV]) and in-
duction of general anaesthesia with ketamine (3 mg/kg
bwt [IV]) and midazolam (0.02 mg/kg bwt [IV]), horses
were euthanized by using an overdose of pentobarbital
(80 mg/kg bwt [IV]) at 3, 5, 7 and 9 weeks after injection
of the cells, respectively.
Fluorescence microscopy and Prussian blue staining
The SDFTs were dissected immediately after death, and
a tendon segment including the lesion was harvested
from between 4 and 5 cm proximal to the surgical scar.
These specimens were stored for 96 h in 4 % parafor-
maldehyde followed by 96 h in PBS. Thereafter they
were snap-frozen in Tissue-Tek (Sakura, Alphen aan den
Rijn, The Netherlands) at −180 °C. Transverse sections
with a thickness of 10 μm were cut with a cryostat and
distended on histology slides. Sections were fixed with
4 % paraformaldehyde for 10 min, washed with PBS and
stored at −80 °C after drying until required. Slices
were examined under a fluorescence microscope (20×
magnification). A set of frozen sections was stained
with Prussian blue as described elsewhere (immuno-
histochemistry world) and examined with a light
microscope (20× magnification).
Immunohistochemistry and immunofluorescence
The cell culture and frozen tissue sections were analysed
immunohistochemically and with immunofluorescence
to detect the GFP antigen. Incubations with the primary
polyclonal antibody rabbit-Anti-CopGFP (Evrogen AB
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513; Evrogen, Moscow, Russia) diluted at 1:1000 were
carried out overnight at 4 °C. After incubation with the
primary antibody, one set of sections was incubated with
a biotylinated swine-anti-rabbit secondary antibody
(E0431; Dako, Hamburg, Germany) at a dilution of 1:400
for 60 min at room temperature. Thereafter, the peroxid-
ase streptavidin-biotin-complex (ABC) detection system
(Vectastain Elite ABC Kit; Vector Laboratories Inc.,
Burlingame, CA, USA) was applied and slices were
exposed to diaminobenzidine tetrachloride (DAB) sub-
strate (Sigma-Aldrich, St. Louis, MO, USA) in accord-
ance with the instructions of the manufacturer. A
second set of sections was incubated with a secondary
goat-anti-rabbit antibody Alexa 546 (Molecular Probes)
at a dilution of 1:1000. Finally, the sections were
counterstained with 4′,6-diamidino-2-phenylindole (DAPI)
(D9542; Sigma-Aldrich) diluted at 1:2000. Cop-GFP trans-
fected control cells functioned as positive controls. In the
negative control sections, the primary antibody was
omitted. During microscopy of all slices, the number
of cells with a positive signal was estimated subject-
ively (low/moderate/high numbers).
Results
Creation of lesions
Horses 2 (left front) and 4 (both, right front > left front)
developed a cellulitis. This was accompanied by the devel-
opment of lameness, which started at 1 day after surgery
and persisted for 5 days in horse 2. In horse 4, lameness
started at 6 days after lesion creation and lasted for 2 days.
Both horses received cefquinome for 7 days (1 mg/kg bwt
[intramuscularly]).
Histology of AT-MSCs in cell culture
Labelled AT-MSCs could be successfully detected in cell
culture with fluorescence microscopy (Figs. 1, 3) and
with immunohistochemistry and immunofluorescence
by using DAB and Alexa 546, respectively (Fig. 3).
Histological tracking of GFP-labelled AT-MSCs
With fluorescence microscopy (Fig. 4, 5) immunohis-
tochemistry and immunofluorescence (Fig. 5), high
numbers of AT-MSCs expressing GFP antigen were
detected at and near the site of injection 3, 5, 7 and
9 weeks after intralesional injection in all horses. At
visual inspection, there was a tendency of finding less
labelled AT-MSCs with increasing time after implant-
ation in sequential samples taken from different
horses, respectively (Fig. 4). SPIO particles incorpo-
rated into AT-MSCs were detected by use of Prussian
blue staining in horses 1, 2 and 4 (Fig. 6).
MRI tracking of SPIO-labelled AT-MSCs
In horse 4, areas with hypointense signal, representing a
magnetic susceptibility artefact resulting from SPIO par-
ticles, surrounded by regions of increased signal inten-
sity, were detectable on transverse T2*-weighted MRI
images in and around the SDFT at days 2, 18, 47 and 62
after treatment (Fig. 7a). T1-weighted images also
showed a negative contrast in the lesions and in their
lateral periphery (Fig. 7c). Areas of signal void corre-
sponded to the two sites of injection in both sequences.
In horse 2, a corresponding finding was present at 6 and
33 days after treatment. As compared with the contralat-
eral SDFT, areas of decreased signal intensity were
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Fig. 3 Photomicrographs of GFP-labelled equine AT-MSCs from horse 1 in cell culture. In the upper row, GFP-fluorescence, anti-GFP
immunohistochemistry (DAB) and merged images are shown. In the lower row, GFP-fluorescence, anti-GFP immunofluorescence
(Alexa 546) and merged images of AT-MSCs (passage 6) are shown. Magnification: 20×. AT-MSC adipose tissue-derived mesenchymal
stromal cell, DAB diaminobenzidine tetrachloride, DAPI 4′,6-diamidino-2-phenylindole, GFP green fluorescent protein
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diffusely defined and markedly extended to the lateral
subcutis in T2* and T1 sequences (Fig. 7).
Discussion
Main findings
The results of the present study show the potential of
standing low-field MRI using T2*- and T1-weighted
sequences to track SPIO-labelled AT-MSCs in vivo
over a period of at least 9 weeks. It is further shown
that GFP-labelled AT-MSCs can be successfully de-
tected in and near surgically induced equine SDFT
lesions between 3 to 9 weeks after intralesional injection
by using fluorescence microscopy, immunofluorescence,
immunohistochemistry and Prussian blue staining.
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Fig. 4 Photomicrographs of superficial digital flexor tendon lesions 3, 5, 7 and 9 weeks after transplantation of GFP-labelled autologous adipose
tissue-derived mesenchymal stromal cells. Bright field, DAPI nuclear stain and GFP-fluorescence and merged images taken from horses 1–4 are shown.
Transplanted cells were positive in the cytoplasm for GFP. Magnification: 20×. DAPI 4′,6-diamidino-2-phenylindole, GFP green fluorescent protein
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Fig. 5 Photomicrographs of a superficial digital flexor tendon lesion 3 weeks after transplantation of GFP-labelled autologous adipose tissue-derived
mesenchymal stromal cells. In the upper row, bright field, GFP-fluorescence, anti-GFP immunohistochemistry (DAB) and merged (arrows: positive cells)
images are shown. In the lower row, DAPI nuclear stain, GFP-fluorescence, anti-GFP immunofluorescence (Alexa 546) and merged images (horse 1) are
shown. Approximately 50 % of the cells were positive for GFP in their cytoplasm. Magnification: 20×. DAB diaminobenzidine tetrachloride,
DAPI 4′,6-diamidino-2-phenylindole, GFP green fluorescent protein
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AT-MSCs versus MSCs from other sources
In a previous study, immunophenotyping of equine MSCs
showed that MSCs from different sources vary in their ex-
pression of MSC-defining antigens [22], suggesting that a
deliberate choice of the cell type is important for the treat-
ment of tendinopathy. In the present study, AT-MSCs
were used because comparative in vitro investigations on
the potential suitability for the treatment of tendinopathy
made obvious that AT-MSCs express extracellular matrix
proteins and tendon markers at significant rates, suggest-
ing an outstanding potential of adipose-derived MSCs for
the treatment of tendinopathy [11].
Up to now, data about cellular homing of AT-MSCs
were available for a period of merely 7 days after im-
plantation of the cells, which had been labelled with
quantum dots (nanocrystals) in a collagenase model of
equine tendinopathy [12]. Results of the present study
prove the traceability of AT-MSCs labelled with GFP
near the injection site for up to at least 9 weeks (62 days).
By contrast, in a different study, the number of equine
BM-MSCs decreased significantly after 10 days. At the
same time, equine ESCs were constantly traceable in
high numbers until 90 days after injection by using a la-
belling technique similar to the one in the present study
[10]. These findings demonstrate the existence of differ-
ences between MSCs from different tissue sources and
emphasize the necessity to research the fate of different
types of equine MSCs separately, dose-dependently and
for a period of time longer than in the present study.
The number of cells injected in the present study
was relatively high and reflects current practice in
equine orthopaedics. In contrast to the high numbers
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Fig. 6 Photomicrographs of surgically created superficial digital flexor tendon lesions treated with autologous AT-MSCs and stained with Prussian blue.
a, b, d Lesions treated with SPIO-labelled AT-MSCs (horses 1, 2 and 4). c Lesion treated with non-SPIO-labelled AT-MSCs (horse 3). Magnifications: 10×
(a-d) and 20× (A/1-D/1). AT-MSC adipose tissue-derived mesenchymal stromal cell, SPIO superparamagnetic iron oxide
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of GFP-positive AT-MSCs after 9 weeks during the
present investigation, consistent GFP expression of ovine
BM-MSCs could be detected at day 7 but no longer at day
14 after injection of 0.5 and 1 × 106 cells in a recent ovine
experimental tendinopathy study [23].
Relevance of finding
The tendency of finding fewer labelled AT-MSCs at
visual inspection with increasing time after implantation
in the sequential samples taken from different horses
suggests a decrease of the cells over time. Nevertheless,
high numbers of cells were still present in and near the
lesion site for up to 9 weeks after treatment. It has been
postulated that the beneficial effects of MSCs on tendon
healing observed clinically [24] and experimentally [3] in
studies may be the result of either de novo formation of
tendon-like tissue (i.e., a true regenerative effect via
engraftment and differentiation) or through modulatory
paracrine actions of the cells by the production of cyto-
kines and growth factors [25]. From the findings of the
present study, it can be concluded that cells remain at
the lesion site for a sufficiently long period after AT-
MSC treatment of equine tendinopathy and that both
pathways are possible. This conclusion further supports
the clinical use of MSCs in horses with centrally located
tendinopathy of the SDFT and may be an explanatory
factor for the clinical observation that stem cell therapy
results in a significantly lower number of re-injuries than
other treatments for tendinopathy in the horse [6, 7, 26].
Reliability of the techniques
The transfection rate of cultured MSCs with reporter
genes expressing GFP was approximately 99 % in the
cells used for injection, as shown by flow cytometric
analysis during passage 0. Fluorescence microscopy dur-
ing passage 1 and flow cytometric analysis during pas-
sage 2 showed that the percentage of transfected MSCs
had a tendency to decrease during early passages. This
finding agrees with previous observations and is poten-
tially caused by transgene silencing caused by epigenetic
downregulation of transgenes leading to mosaic expres-
sion patterns [27, 28]. However, lentiviral vectors encod-
ing GFP have been shown to lack significant negative
effects on survival and differentiation potential of MSCs
in vitro [28]. The transfection of cultured MSCs with re-
porter genes expressing GFP was successful for tracking
AT-MSCs up to 9 weeks after implantation, which
proves the suitability of this technique for AT-MSCs
implanted into tendon defects as previously described
for BM-MSCs and ESCs [10]. The labelling of MSCs
with GFP by viral transfection is an established method
in experimental animal studies [23, 29, 30]. The detec-
tion of GFP under fluorescence microscopy might be
impaired by natural fluorescence of cell metabolites and
structural components such as collagen in tissue speci-
men [31]. This phenomenon referred to as “autofluores-
cence” did not impair interpretation in the present study
significantly as verified by immunohistochemical stain-
ing and immunofluorescence of GFP-expressing cells
using DAB and Alexa 546 and by counterstaining of cell
nuclei with DAPI.
In the present study, SPIO-labelled AT-MSCs could be
detected with MRI in the lesion and its lateral periphery
up to 9 weeks after implantation. The presence of SPIO
particles was proved successfully with Prussian blue
staining of tendon tissue post-mortem. Labelling of
MSCs with SPIO particles has been previously used to
track MSCs successfully in laboratory rodents and sheep
[23, 32, 33]; the procedure affects their viability to some
extent but insignificantly, although their proliferative
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Fig. 7 Transverse magnetic resonance imaging images of SDFT
lesions treated with 10 × 106 SPIO-labelled AT-MSCs or saline. a, c
A focal, moderately demarcated hypointense area is evident in
and lateral to the AT-MSC-treated SDFT lesion, area indicated by
arrowheads in a. b, d Signal intensity of the saline treated
lesion is increased in the contralateral SDFT, area indicated by
asterisk in b. a, b: T2*-weighted sequence, 47 days after
injection. c, d: T1-weighted sequence, 62 days after injection; horse
4. AT-MSC adipose tissue-derived mesenchymal stromal cell, SDFT
superficial digital flexor tendon, SPIO superparamagnetic iron oxide
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capacity may be decreased [16, 17, 23, 32]. In a recent
equine study, SPIO-labelled BM-MSCs could be suc-
cessfully detected in cadaveric SDFTs by using 1.5-
Tesla MRI [16]. The present study shows that SPIO
labelling is also a practicable technique to track AT-
MSCs injected in surgically created tendon lesions
with 0.27-Tesla MRI in live horses in T2*-weighted
sequences with the aid of the susceptibility artefact.
Detection of SPIO particles was also successful in
T1-weighted sequences, accepting a less distinct de-
marcation of the intact tendon tissue. The use of
ultra-small SPIO particles might have increased the
contrast in T1-weighted sequences. Alternative se-
quences, potentially appropriate to monitor SPIO-
particles (e.g., 3DT1), were not available for the
standing low-field MRI used in the present study. An-
gulation of the SDFTs relative to the magnetic field,
using the magic angle effect, would probably have
further improved MRI of SPIO particles [33]. Vaguely
demarcated hypointense areas in the subcutis at the
injection site helped to identify the sites of injection,
especially in T1-weighted sequences. These signal
voids are a potential sign of migration of the injected
MSCs or of reflux of the cell suspension during or
after injection. Although no resistance of the syringe
plunger was encountered during injection, alternative
injection techniques should be considered to avoid
reflux from tendon lesions.
The present study proves that co-labelling of equine
AT-MSCs with a lentiviral copGFP promotor and SPIO
particles is feasible. Whether the procedure affects the
biological activity of the cells (and, if so, to what extent)
remains uncertain [23].
Alternative techniques to track MSCs are labelling
with nanocrystals, which are resistant to metabolic
degradation and have few cytotoxic effects [34, 35], and
with technetium-99 hexamethyl propylene amine oxime,
which allows detection of cells by nuclear scintigraphy
but only for 24 h after administration [36]. Both tech-
niques have been used successfully in experimentally
induced equine tendon lesions [12, 37].
Cellulitis
Horses 2 and 4 developed mild cellulitis after surgical
induction of the lesions, the former in the limb
treated with SPIO-labelled AT-MSC, the latter in both
limbs but predominantly in the control limb. This
complication most likely can be attributed to the
surgical procedure or the aftercare during the days
after surgery (or both), as clinical signs started before
injection of AT-MSCs. Metaphylactic treatment with
antimicrobials might have decreased the risk. However,
a deliberate choice was made not to do this as there is
evidence that some antimicrobials have the potential to
influence tendon metabolism: oxytetracycline showed
in vitro inhibition of suspensory ligament myofibroblast
contractility [38], and oral doxycycline administration
leads to inhibition of matrix metalloproteinase-13
(MMP-13) in rat tendons [39]. Cellulitis was restricted to
the subcutaneous area and there were no indications that
it extended into the created core lesion. Hence, no direct
effect on migration behaviour of the cells could be ex-
pected. Nor are there indications that the cellulitis has
hampered the modalities used in the present study to
track implanted cells in any way.
Limitations
The present study’s crucial limitation was that the
number of labelled cells was not counted but deter-
mined semi-quantitatively in post-mortem specimen.
The fact that in the present study 10 × 106 AT-MSCs
were implanted but that Guest et al. [10] injected 1 ×
106 BM-MSCs or ESCs might have influenced the re-
sults. This holds true also for the use of different
models of tendinopathy in the present compared with
other studies [10, 12]. Only a small number of horses
were included in the present pilot study, and a stag-
gered approach was chosen to monitor the presence
of AT-MSCs over time. Therefore, the potential im-
pact of inter-individual variations (e.g., age, gender
and local infection) on the outcome cannot be deter-
mined on the basis of the present results. Tissue from
the opposite front-limb SDFT was not examined his-
tologically in the present study, but Carvalho et al.
[12] could not detect AT-MSCs in the contralateral
SDFT 7 days after intralesional injection of the ipsi-
lateral SDFT. Histological tracking of MSCs in the re-
gional lymph node (Lnn. axillares superficiales) using
the techniques presented here should be included in
future studies to further characterize AT-MSC distri-
bution after injection. Another limitation is that the
signal intensity change was not quantified objectively
on MRI images. The loss of signal intensity may be
objectified and a threshold may be established.
Conclusions
Conclusively, standing low-field MRI has the potential
to track SPIO-labelled AT-MSCs in surgically induced
SDFT lesions for up to 9 weeks in vivo, as demon-
strated by the detection of large numbers of labelled
cells with histology, immunofluorescence and immu-
nohistochemistry in post-mortem specimen of the
lesions. Injection techniques have to be chosen delib-
erately to avoid reflux of the cell substrate injected.
In future dose-dependent controlled clinical trials,
numbers of cells retrieved in the tendons should be
quantified and horses should be monitored for a lon-
ger period of time.
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